Floatz logo

MDM2 INHIBITOR AMG-232

Plasmacytoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Plasmacytoma cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Memorial Sloan Kettering Cancer Center
Phase 2B
cc-5013
Memorial Sloan Kettering Cancer Center
Phase 2B
Evomela
M.D. Anderson Cancer Center
Phase 2B
Busulphan
M.D. Anderson Cancer Center
Phase 2B
Pomalidomide
Mayo Clinic
Phase 2B

View all 12 →

Same molecule, other indications

MDM2 INHIBITOR AMG-232 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
Mantle Cell Lymphoma and Diffuse Large B Cell LymphomaDormant
CC
Indicative ·
41 / 100
View asset →
B-cell neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →